PIK3CA and cancer: MEN1611, similar to alpelisib, targets with the highest potency the p110α wild-type and mutated isoforms, but is more effective than alpelisib in inhibiting the growth of cancer cell lines with PIK3CA-wt and PTEN-loss genetic background.